Comprehensive evaluation index system of clinical breast cancer drugs
Objective To establish a comprehensive evaluation index system for breast cancer treatment drugs in China,and to assess the comprehensive value of drugs from multiple dimensions to support clinical rational use.Methods Literature review and expert consultation were conducted to collect evidence that establishes a system of an evaluation framework and specific evaluation indices.Further modify the comprehensive assessment framework to determine the final assessment index system.Weigh each indicator by the appropriate algorithm and define the corresponding scoring rules.Results The positivity coefficient of 15 consulting experts is 1.00,the average authority is 0.90,and the opinion coordination coefficients of the importance and feasibility were 0.305 and 0.336.With this evaluation frame,there were six first-level indicators which include safety,efficacy,economy,innovation,appropriateness,and accessibility in this system,which consists with 14 second-level indicators.safety,economy,appropriateness,and accessibility each for 2,efficacy and innovation each for 3.Among them,effectiveness,safety and economy are given higher weights,with 39,19 and 14 points respectively.Conclusion The comprehensive drug evaluation index system constructed in this study meets the needs of drug value assessment for breast cancer,which can provide experience reference for exploration of clinical value-based drug evaluation system.
clinical comprehensive evaluation of drugsevaluation indexbreast cancerrational drug usedrug value
NETL
NSTL
万方数据
